on Isomorphic Labs
Isomorphic Labs Secures $5 Billion in Series C Funding
Isomorphic Labs, an AI-focused company in drug development, has announced the completion of a $5 billion Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with significant contributions from Andreessen Horowitz and Alphabet. Existing investors, such as Thrive Capital and Temasek, also participated.
The funding will enhance the development of Isomorphic's drug design engine, IsoDDE, which employs AI models to explore chemical spaces and refine drug design. IsoDDE aims to transform biological systems predictions, supporting advances across a pipeline of therapeutic candidates.
The capital will drive expansion into new biological models and support clinical trial infrastructure. CEO Sir Demis Hassabis emphasized the potential for AI in understanding biology at a molecular level and speeding up drug discovery.
Investors express confidence in Isomorphic's transformative approach to medicine, noting its capacity for breakthroughs in AI-led drug discovery.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Isomorphic Labs news